Effect of a sugar replacement on blood sugar levels in healthy adults
Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
This study tests if a sugar replacement called Oligomate® can help keep blood sugar levels lower after meals in healthy adults.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of Aberdeen Academic / other |
| Locations | 1 site (Aberdeen) |
| Trial ID | NCT06714552 on ClinicalTrials.gov |
What this trial studies
This study investigates how Oligomate®, a beta-galacto-oligosaccharide, affects blood sugar levels after meals in healthy adults. Participants will consume a beverage containing either Oligomate® or glucose, and their blood samples will be collected at various time points to measure glucose and insulin levels. The study is designed as a single-blind, randomized, controlled, cross-over trial, ensuring that each participant serves as their own control. The aim is to determine if this sugar replacement can lower postprandial hyperglycemia, potentially benefiting metabolic health.
Who should consider this trial
Good fit: Ideal candidates are healthy men and women aged 18 to 65 with a BMI between 18.5 and 29.9.
Not a fit: Patients with diabetes or any endocrine diseases, as well as those on medications affecting blood glucose levels, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new dietary approach to help manage blood sugar levels and reduce the risk of metabolic diseases.
How similar studies have performed: Other studies have shown promise in using sugar replacements to manage blood glucose levels, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy Men or Women * Body Mass Index (BMI) 18.5-29.9 kg/m\^2 * Between 18 and 65 years of age * Compliant (i.e., understands and is willing, able, and likely to comply with the experimental procedure and safety guidelines) * Able to provide informed consent * Premenopausal women must have a regular cycle or be on hormonal contraception. Exclusion Criteria: * Diabetes mellitus (all types including gestational diabetes) * HbA1c result over the study limit \[healthy range of between 4% and 5.9%\] * Endocrine disease (e.g., Cushing's syndrome) * Any food allergy or intolerance, or following Vegan diet * Medications that increase blood glucose (e.g., steroids, protease inhibitors, antipsychotics, antihypertensives, statins, diuretics, nicotinic acid, etc.) * Medications that lower glycemia (e.g., anti-hyperglycaemics, insulin, beta- blockers, etc.) * Medication affecting glucose regulation, appetite, and/or digestion/absorption of nutrients, antibiotics * Major medical or surgical event requiring hospitalization in the previous 3 months * Pregnant or lactating * Participation in another clinical/supplementation trial or actively trying to reduce body weight * Unable to comply with experimental procedures and safety guidelines * Unable to give consent * Smokers * Travel during the study period
Where this trial is running
Aberdeen
- University of Aberdeen, Rowett Institute — Aberdeen, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Karen Scott, PhD — University of Aberdeen
- Study coordinator: Karen Scott, PhD
- Email: k.scott@abdn.ac.uk
- Phone: +44 (0)1224 438730
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.